"Philip Morris delivered genuine momentum with full-year revenue surpassing $40 billion, driven by a smoke-free business that generated close to $17 billion, representing 41.5% of total net revenues."
"Altria took $2.2 billion in total non-cash impairment charges on NJOY in 2025, while its cigarette volume fell 10.0% for the full year, indicating significant challenges."
"Philip Morris restructured its organization into three segments, signaling a commitment to transition, with targets of 6%-8% organic revenue growth and 9%-11% adjusted EPS growth through 2028."
Philip Morris reported over $40 billion in revenue for 2025, with significant growth in smoke-free products, which now account for 41.5% of total revenues. ZYN and IQOS saw substantial increases in sales, while Altria faced challenges, including $2.2 billion in impairment charges related to NJOY. Altria's cigarette volumes and market share declined, indicating a defensive strategy. In contrast, Philip Morris restructured for growth, targeting 6%-8% organic revenue growth and focusing on reducing debt without share repurchases planned for 2026.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]